Aptose Biosciences Inc. (APS.TO)
CAD 0.27
(0.0%)
CAD 0.27
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 621 Thousand USD | -38.02% |
| 2022 | 1 Million USD | 771.3% |
| 2021 | 115 Thousand USD | -78.5% |
| 2020 | 535 Thousand USD | -47.08% |
| 2019 | 1.01 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | -100.0% |
| 2014 | 486.24 Thousand USD | -0.07% |
| 2013 | 486.6 Thousand USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | -100.0% |
| 2007 | 12.81 Million USD | 14.81% |
| 2006 | 11.16 Million USD | 11.7% |
| 2005 | 9.99 Million USD | 22.79% |
| 2004 | 8.13 Million USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 520 Thousand USD | 0.0% |
| 2024 Q2 | 414 Thousand USD | 0.0% |
| 2023 Q3 | 720 Thousand USD | -11.87% |
| 2023 Q1 | 918 Thousand USD | -8.38% |
| 2023 Q2 | 817 Thousand USD | -11.0% |
| 2023 Q4 | 621 Thousand USD | -13.75% |
| 2023 FY | 621 Thousand USD | -38.02% |
| 2022 Q2 | 3000.00 USD | -70.0% |
| 2022 Q1 | 10 Thousand USD | -91.3% |
| 2022 Q3 | 1000.00 USD | -66.67% |
| 2022 Q4 | 1 Million USD | 100100.0% |
| 2022 FY | 1 Million USD | 771.3% |
| 2021 Q2 | 321 Thousand USD | -23.57% |
| 2021 Q3 | 218 Thousand USD | -32.09% |
| 2021 Q4 | 115 Thousand USD | -47.25% |
| 2021 FY | 115 Thousand USD | -78.5% |
| 2021 Q1 | 420 Thousand USD | -21.5% |
| 2020 Q4 | 535 Thousand USD | -18.69% |
| 2020 Q3 | 658 Thousand USD | -15.21% |
| 2020 Q2 | 776 Thousand USD | -13.2% |
| 2020 Q1 | 894 Thousand USD | -11.57% |
| 2020 FY | 535 Thousand USD | -47.08% |
| 2019 Q3 | 1.12 Million USD | -7.49% |
| 2019 Q1 | 1.32 Million USD | 0.0% |
| 2019 Q4 | 1.01 Million USD | -10.05% |
| 2019 FY | 1.01 Million USD | 0.0% |
| 2019 Q2 | 1.21 Million USD | -8.09% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 FY | - USD | -100.0% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q2 | 486.6 Thousand USD | -18.58% |
| 2014 Q4 | 486.24 USD | -18.96% |
| 2014 Q1 | 597.66 Thousand USD | -2.83% |
| 2014 FY | 486.24 Thousand USD | -0.07% |
| 2014 Q3 | 600.02 USD | -99.88% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | 615.06 Thousand USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 FY | 486.6 Thousand USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q3 | 12.34 Million USD | -3.63% |
| 2008 FY | - USD | -100.0% |
| 2008 Q4 | - USD | -100.0% |
| 2008 Q1 | 12.74 Million USD | 4.78% |
| 2008 Q2 | 12.81 Million USD | 0.55% |
| 2007 FY | 12.81 Million USD | 14.81% |
| 2007 Q1 | 9.98 Million USD | -0.46% |
| 2007 Q3 | 11.23 Million USD | 0.62% |
| 2007 Q4 | 12.16 Million USD | 8.31% |
| 2007 Q2 | 11.16 Million USD | 11.81% |
| 2006 Q4 | 10.02 Million USD | -1.2% |
| 2006 Q3 | 10.15 Million USD | 1.59% |
| 2006 Q2 | 9.99 Million USD | 5.47% |
| 2006 FY | 11.16 Million USD | 11.7% |
| 2006 Q1 | 9.47 Million USD | 0.0% |
| 2005 Q4 | - USD | -100.0% |
| 2005 Q3 | 8.75 Million USD | 7.57% |
| 2005 Q2 | 8.13 Million USD | 51.49% |
| 2005 Q1 | 5.37 Million USD | 103.93% |
| 2005 FY | 9.99 Million USD | 22.79% |
| 2004 FY | 8.13 Million USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q4 | 2.63 Million USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Appili Therapeutics Inc. | 875.2 Thousand CAD | 29.045% |
| Eupraxia Pharmaceuticals Inc. | - CAD | -Infinity% |
| Helix BioPharma Corp. | - CAD | -Infinity% |
| Microbix Biosystems Inc. | 6.37 Million CAD | 90.266% |
| Medicenna Therapeutics Corp. | - CAD | -Infinity% |
| Satellos Bioscience Inc. | - CAD | -Infinity% |
| Oncolytics Biotech Inc. | 290 Thousand CAD | -114.138% |
| Sernova Corp. | - CAD | -Infinity% |